• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Humulin 70/30
    / Eli Lilly

    Active Ingredient
    Insulin Human 100 IU/ml

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    10 ml

    full basket chart

    Related information


    Paediatric population: No data are available.
    Method of administration:  Humulin Isophane and Mixtures in vials and Humulin Isophane and Mixtures in cartridge presentations should be given by subcutaneous injection but may, although not recommended, also be given by intramuscular injection. These formulations should not be administered intravenously.
    Subcutaneous administration should be in the upper arms, thighs, buttocks or abdomen. Use of injection sites should be rotated so that the same site is not used more than approximately once a month.
    Care should be taken when injecting any Humulin insulin preparations to ensure that a blood vessel has not been entered. After any insulin injection, the injection site should not be massaged. Patients must be educated to use proper injection techniques.
    A patient’s treatment regimen should be based on their individual metabolic requirements.
    Each pack contains a patient information leaflet with instructions on how to inject insulin.
    See prescribing information for full details.


    For the treatment of patients with diabetes mellitus who require insulin for the maintenance of
    glucose homeostasis.


    Hypersensitivity to Humulin or to the formulation excipients, unless used as part of a desensitisation programme.
    Under no circumstances should any Humulin formulation other than Humulin Soluble be given intravenously.

    Special Precautions

    See prescribing information for full details.

    Side Effects

    Hypoglycaemia is the most frequent undesirable effect of insulin therapy that a patient with diabetes may suffer. Severe hypoglycaemia may lead to loss of consciousness, and in extreme cases, death. No specific frequency for hypoglycaemia is presented, since hypoglycaemia is a result of both the insulin dose and other factors e.g. a patient`s level of diet and exercise.
    Local allergy in patients is common (1/100 to < 1/10). Redness, swelling, and itching can occur at the site of insulin injection. This condition usually resolves in a few days to a few weeks. In some instances, local reactions may be related to factors other than insulin, such as irritants in the skin cleansing agent or poor injection technique.
    See prescribing information for full details.


    Drug interactions

    A number of medicinal products are known to interact with glucose metabolism and therefore the physician should be consulted when using other medications in addition to human insulin. The physician must therefore take possible interactions into account and should always ask his patients about any medicinal products they take.
    Insulin requirements may be increased by substances with hyperglycaemic activity, such as, glucocorticoids, thyroid hormones, growth hormone, danazol, beta2-sympatomimetics (such as ritodrine, salbutamol, terbutaline) and thiazides.
    Insulin requirements may be reduced in the presence of substances with hypoglycaemic activity, such as oral hypoglycaemics (OHA), salicylates (for example, acetylsalicylic acid), certain antidepressants (monoamine oxidase inhibitors), certain angiotensin converting enzyme (ACE) inhibitors (captopril, enalapril), angiotensin II receptor blockers, non-selective beta-blocking agents and alcohol.
    Somatostatin analogues (octreotide, lanreotide) may both decrease or increase insulin dose requirements.

    Pregnancy and Lactation

    It is essential to maintain good control of the insulin treated (insulin-dependent or gestational diabetes) patient throughout pregnancy. Insulin requirements usually fall during the first trimester and increase during the second and third trimesters. Patients with diabetes should be advised to inform their doctors if they are pregnant or are contemplating pregnancy.
    Careful monitoring of glucose control, as well as general health, is essential in pregnant patients with diabetes.
    Patients with diabetes who are lactating may require adjustments in insulin dose and/or diet.


    Insulin has no specific overdose definitions, because serum glucose concentrations are a result of complex interactions between insulin levels, glucose availability and other metabolic processes. Hypoglycaemia may occur as a result of an excess of insulin relative to food intake and energy expenditure.
    Hypoglycaemia may be associated with listlessness, confusion, palpitations, headache, sweating and vomiting.
    Mild hypoglycaemic episodes will respond to oral administration of glucose or sugar products.
    Correction of moderately severe hypoglycaemia can be accomplished by intramuscular or subcutaneous administration of glucagon, followed by oral carbohydrate when the patient recovers sufficiently. Patients who fail to respond to glucagon must be given glucose solution intravenously.
    If the patient is comatose, glucagon should be administered intramuscularly or subcutaneously.
    However, glucose solution must be given intravenously, if glucagon is not available or if the patient fails to respond to glucagon. The patient should be given a meal as soon as consciousness is recovered.
    Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may occur after apparent clinical recovery.

    Important notes

    Incompatibilities: Humulin preparations should not be mixed with insulins produced by other manufacturers or with animal insulin preparations.
    Storage: Unused vials and Cartridges: Store in a refrigerator (2°C – 8°C). Do not freeze. Do not expose to excessive heat or direct sunlight.
    In use Vials: Once in use the vials may be used for up to 28 days. Do not use beyond this period. Store below 30°C.
    In use Cartridge: Once in use the cartridges may be used for up to 28 days. Do not use beyond this period. Store below 30°C. The pen with the inserted cartridge should not be stored with the needle attached.

    Eli Lilly, Spain
    Licence holder